Stock Market Reviews

ECOR (electroCore, Inc.) News

Get the latest news, insights, and market updates on ECOR (electroCore, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for
  Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Mar 5, 2026 - $ECOR
• OmniAb, Inc. (OABI) Reports Q4 Loss, Misses Revenue Estimates
  OmniAb, Inc. (OABI) delivered earnings and revenue surprises of -33.33% and -5.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
  Mar 4, 2026 - $ECOR
• electroCore, Inc. (ECOR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
  electroCore (ECOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Mar 4, 2026 - $ECOR
• Amneal Pharmaceuticals (AMRX) Q4 Earnings Top Estimates
  Amneal (AMRX) delivered earnings and revenue surprises of +18.85% and -0.19%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
  Feb 27, 2026 - $ECOR
• Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore’s gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder (“PTSD”)
  ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society have launched a new research initiative to explore the extent to which gammaCore™ Sapphire, electroCore’s non-invasive vagus nerve stimulator (nVNS), can be used as an adjunctive treatment of symptoms associated with PTSD. The study entitled “Non-Invasive Vagus Nerve Stimulation (nV
  Jan 21, 2026 - $ECOR
• electroCore Provides Preliminary Full-Year 2025 Business Update; Expects ~26% Revenue Growth to ~$31.8–$32.0 Million
  Record revenue of approximately $31.8 - $32.0 million for full-year 2025 and approximately $9.0 - $9.2 million for the three months ended December 31, 2025 Revenue growth of approximately 26% over full-year 2024Cash, cash equivalents, and marketable securities (“Total Cash”) balance of approximately $11.6 million as of December 31, 2025 ROCKAWAY, N.J., Jan. 20, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today pr
  Jan 20, 2026 - $ECOR
• Analysts Expect Breakeven For electroCore, Inc. (NASDAQ:ECOR) Before Long
  We feel now is a pretty good time to analyse electroCore, Inc.'s ( NASDAQ:ECOR ) business as it appears the company may...
  Dec 24, 2025 - $ECOR
• TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen
  ROCKAWAY, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced the publication of a peer reviewed paper titled “Non-Invasive Transcutaneous Vagal Nerve Stimulation Enhances Mood, Task Performance, and Learning in a High-Stress Military Training Environment” which will be presented at the Applied Human Factors and Ergonomics (AHFE2025) Conference on December 8, 2025. The paper presents result
  Dec 2, 2025 - $ECOR
• Investors in electroCore (NASDAQ:ECOR) from five years ago are still down 74%, even after 28% gain this past week
  electroCore, Inc. ( NASDAQ:ECOR ) shareholders should be happy to see the share price up 28% in the last week. But will...
  Nov 13, 2025 - $ECOR
• electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
  ROCKAWAY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The conference will take place in New York on Thursday, November 20, 2025 at The Westin NY Grand Central Hotel. Management will host one-on-one meetings throughout the day. Investors who wish to request a meeting should
  Nov 10, 2025 - $ECOR